EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?

Auriane de Pellegars-Malhortie, Laurence Picque Lasorsa, Thibault Mazard iD, Fabien Granier, Corinne Prévostel iD

Pharmaceuticals · 16.07.2024 · 17 (7) · 949

DOI: 10.3390/ph17070949 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 16.07.2024. Verfasst von Auriane de Pellegars-Malhortie und 4 weiteren Autor:innen. Beteiligte Einrichtung: IRCM (Montpellier Cancer Research Institute), University of Montpellier, Inserm, ICM (Montpellier Regional Cancer Institute), 34298 Montpellier, CEDE…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 330 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Région Occitianie, la Region Occitanie Pyrénées-Méditerranée.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant progress in cancer prevention, screening, and treatment, the still limited number of therapeutic options is an obstacle towards increasing the cancer cure rate. In recent years, many efforts were put forth to develop therapeutics that selectively target different components of the oncogenic Wnt/β-catenin signaling pathway. These include small molecule inhibitors, antibodies, and more recently, gene-based approaches. Although some of them showed promising outcomes in clinical trials, the Wnt/β-catenin pathway is still not targeted in routine clinical practice for cancer management. As for most anticancer treatments, a critical limitation to the use of Wnt/β-catenin inhibitors is their therapeutic index, i.e., the difficulty of combining effective anticancer activity with acceptable toxicity. Protecting healthy tissues from the effects of Wnt/β-catenin inhibitors is a major issue due to the vital role of the Wnt/β-catenin signaling pathway in adult tissue homeostasis and regeneration. In this review, we provide an up-to-date summary of clinical trials on Wnt/β-catenin pathway inhibitors, examine their anti-tumor activity and associated adverse events, and explore strategies under development to improve the benefit/risk profile of this therapeutic approach.

Schlagwörter

Stichwörter der Autor:innen

ADCWnt/β-catenincancer therapyclinical trialsdrug combinationdrug designdrug profilingnanovectorizationprecision medicinesmall molecule inhibitors

Autor:innen und Institutionen

  • IRCM (Montpellier Cancer Research Institute), University of Montpellier, Inserm, ICM (Montpellier Regional Cancer Institute), 34298 Montpellier, CEDEX 5, France.
  • Medical Oncology Department, ICM, University of Montpellier, CEDEX 5, 34298 Montpellier, France.
  • FGHI, 165 Rue Denis Papin, 34570 Montarnaud, France.

ORCID-Profile: Thibault Mazard, Corinne Prévostel

Förderung

  • Région Occitianie
  • la Region Occitanie Pyrénées-Méditerranée

Zitieren

APA

de Pellegars-Malhortie, A., Picque Lasorsa, L., Mazard, T., Granier, F., & Prévostel, C. (2024). Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?. Pharmaceuticals, 17(7), 949. https://doi.org/10.3390/ph17070949

Vancouver

de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prévostel C. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?. Pharmaceuticals. 2024;17(7):949. doi:10.3390/ph17070949

BibTeX
@article{dePellegarsMalhortie2024,
  author = {de Pellegars-Malhortie, Auriane and Picque Lasorsa, Laurence and Mazard, Thibault and Granier, Fabien and Prévostel, Corinne},
  title = {Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {7},
  pages = {949},
  doi = {10.3390/ph17070949}
}
Kostenlos starten →